This training event is dedicated to clinicians and researchers interested in using the DECIDE applications
for the automatic extraction of disease markers for the Alzheimer's Disease from RMI and PET/SPECT images and EEG traces.
In order to ensure a proper use of the applications and thorough understanding of the results, the DECIDE service is only available to authorised users, who have attended a training and successfully underwent an examination.
For this event, three application tracks are available:
GridSPM (PECT/SPECT diagnostic applications)
GridMRIseg and GridGDI (RMI diagnostic application)
GridEEG (EEG research application)
The event is jointly organised with the DECIDE User Forum
, a one-day interactive event designed to bring together DECIDE early adopters and newly trained users, in order to discuss the exploitation of DECIDE applications in real patients' cases, which will be held on 22 February 2013, at the same GARR headquarters in Rome, Italy.
You are kindly invited to take part in both events.
Please register here
Remote participation is available through the DECIDE e-learning platform. Interested participants can connect to the virtual room: http://connect.ct.infn.it/decide/
and log in as "guest" using their Name, Surname and Organization/Company.
Please note that, also in this case, you are kindly requested to register here, specifying that you're participating remotely.
Starts 21 Feb 2013 09:00
Ends 21 Feb 2013 18:20
via dei Tizii 6,
DECIDE (Diagnostic Enhancement of Confidence by an International Distributed Environment) is a FP7-funded project aiming at implementing a e-Infrastructure and e-Service for the automatic extraction of disease markers for the Alzheimer's Disease from RMI and PET/SPECT images and EEG traces, to be used by researchers and clinicians.
In the project, we have built up a GRID infrastructure enabling the upload of individual structural MRI, resting state FDG-PET, and resting state EEG datasets for an automatic extraction of structural MRI, FDG-PET and candidate EEG markers of Alzheimer’s disease for diagnostic and research purposes. The DECIDE service provides a statistical diagnostic report for any modality (structural MRI, FDG-PET and candidate EEG markers).
Further information on the project is available at: www.eu-decide.eu